Tysabri and Progressive Multifocal Leukoencephalopathy: What You Need to Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Drug Risks

If you or a loved one is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is critical. This rare but serious brain infection has been linked to the medication, and ongoing research continues to refine how we identify and manage those at highest risk. Building on decades of pharmacovigilance, this page explains the known risk factors, FDA safety updates, and monitoring strategies for patients on Tysabri.

Tysabri and PML: A Documented Association

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has mandated a boxed warning for Tysabri, highlighting that the drug increases the risk of PML. The warning states that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri dosing immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Evidence and Mechanistic Pathway

Clinical trial data provide evidence of PML occurrence. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of 1,043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases underscore the importance of risk stratification and monitoring. The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of lymphocytes into the brain. This immunosuppressive effect reduces immune surveillance in the central nervous system, allowing latent JCV to reactivate and cause PML. The risk is particularly elevated in patients with prior immunosuppressant use, as this further compromises immune function. Regarding the adequacy of warnings, the FDA has required a boxed warning and a restricted distribution program, which are among the most stringent regulatory measures. The warning explicitly states that Tysabri increases the risk of PML and lists the known risk factors. Healthcare professionals are instructed to monitor patients and withhold dosing at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, despite these warnings, PML remains a serious adverse event, and patients may still develop the condition even with appropriate monitoring.

Causation Considerations and Risk Timeline

For affected patients, causation considerations involve assessing whether PML is attributable to Tysabri exposure. The known risk factors and the temporal relationship between drug initiation and PML onset are critical. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This timeline suggests that PML can develop after varying durations of exposure, with longer treatment duration being a recognized risk factor. The timeline between Tysabri exposure and documented harm is variable. PML may develop months to years after starting treatment, and the risk increases with longer therapy, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early detection through monitoring for new neurological symptoms is crucial, as withholding Tysabri at the first sign of PML may improve outcomes. In summary, Tysabri is causally linked to PML through a well-established mechanism involving reduced immune surveillance in the brain. The FDA has implemented robust warnings and a restricted distribution program to mitigate this risk. However, PML remains a severe and potentially fatal complication, and patients and healthcare providers must carefully weigh the benefits and risks of Tysabri therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the link between Tysabri and Progressive Multifocal Leukoencephalopathy?

Tysabri (natalizumab) is associated with an increased risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. The FDA has issued a boxed warning and requires a restricted distribution program due to this risk. The mechanism involves reduced immune surveillance in the brain, allowing latent JC virus to reactivate.

What are the risk factors for developing PML while on Tysabri?

Three primary risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How long does it take for PML to develop after starting Tysabri?

PML may develop months to years after starting treatment. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The risk increases with longer therapy, especially beyond two years.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.